Trials / Completed
CompletedNCT05928182
El Faro: Addressing Mental Health Inequities Among Latinx Children With ADHD in Durham
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Duke University · Academic / Other
- Sex
- All
- Age
- 6 Years – 12 Years
- Healthy volunteers
- Accepted
Summary
Study team members from El Futuro in Durham, North Carolina have created an intervention called El Faro. El Faro helps Latinx families of children with ADHD understand and cope with the stress and difficulties presented by the disorder. We propose to develop a community-engaged research partnership between El Futuro and the Duke ADHD Program that aims to pilot-test an adapted El Faro treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | El Faro Treatment Intervention | Pre - Measures: complete Child Behavior Checklist (CBCL), ADHD module of the MINI International Neuropsychiatric Interview for Children and Adolescents (MINI) administered by study team, ADHD Rating Scale (ADHD-RS; parent and teacher ratings), ADHD Functional Impartment Scale (ADHD-FX), Parenting Sense of Competence (PSOC), demographic information, and medical history. \[All rating scales are parent-report unless noted otherwise\] Treatment: Complete an 8-week adapted El Faro treatment intervention with homework tasks. Post-Measures: CBCL, ADHD-RS (parent and teacher ratings), ADHD-FX, and PSOC. We will also acceptability and feasibility via measuring session attendance (rated by the therapist each session), homework completion (rated by the therapist each session), 7 treatment acceptability questions. \[All rating scales are parent-report unless noted otherwise and administered at post-treatment visit unless noted otherwise\]. |
Timeline
- Start date
- 2023-10-10
- Primary completion
- 2024-05-30
- Completion
- 2024-05-30
- First posted
- 2023-07-03
- Last updated
- 2024-07-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05928182. Inclusion in this directory is not an endorsement.